The Long-Term Clinical Effectiveness of Ustekinumab in Antitumor Necrosis Factor-Experienced Crohn’s Disease Patients

Background Crohn’s disease (CD) is a chronic inflammatory bowel disease (IBD) of unknown etiology. Ustekinumab (UST), an interleukin (IL)-12 and IL-23 antibody, has been approved in the recent years to treat IBD, both Crohn’s disease and ulcerative colitis. This study clarifies the long-term effecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Altuwaijri, Mansour, Hakami, Loai, Alharbi, Othman, Almadi, Majid, Alshankiti, Suliman, Aljebreen, Abdulrahman, Azzam, Nahla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9514158/
https://www.ncbi.nlm.nih.gov/pubmed/36185868
http://dx.doi.org/10.7759/cureus.28536

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9514158/
https://www.ncbi.nlm.nih.gov/pubmed/36185868
http://dx.doi.org/10.7759/cureus.28536

Ejemplares similares